A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/26/2018
Start Date:August 1, 2018
End Date:September 2020
Contact:Heidi Matthews
Email:heidi.matthews@precisionformedicine.com
Phone:(603) 731.5558

Use our guide to learn which trials are right for you!

A Phase 1, Open-label Study of the Safety, Pharmacokinetics and Efficacy of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors

RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase. The purpose of this
study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of RX108 in
patients with locally advanced or metastatic solid tumors.

This is a open-label, two-part study comprised of a dose escalation part and a dose expansion
part. In the dose escalation part, RX108 will be administered in ascending doses to evaluate
the safety and tolerability of RX108 and determine the maximum tolerated dose (MTD) and/or
recommended Phase 2 dose (RP2D). The dose expansion part will assess the safety,
pharmacokinetics, and efficacy of RX108 at the RP2D.

Inclusion Criteria:

- Histologically confirmed locally advanced or metastatic cancer that has failed all
systemic therapies known to confer clinical benefit

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Minimum age of 18 years

- Adequate hematologic, hepatic and renal function

- Written Informed Consent

- Must agree to use adequate contraception (females and males)

Exclusion Criteria:

- History of certain cardiac abnormalities

- History of inadequate pulmonary function

- Symptomatic brain metastasis

- Treatment with prohibited medications

- Known contra-indication to digoxin

- Treatment with any unapproved therapies for cancer, or any other anti-cancer therapy
within 3 weeks

- Any toxicity related to prior treatment must have resolved to Grade 1 or less, with
the exception of alopecia

- Clinically significant active infection requiring systemic antibiotic treatment

- Females who are pregnant or breastfeeding
We found this trial at
2
sites
Los Angeles, California 90048
Principal Investigator: Monica Mita, MD
Phone: 310-967-2795
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: Siqing Fu, MD
Phone: 713-792-5025
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials